Introduction： OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share with you our preclinical pharmacological evaluation platform for T cell engagers. https://onco.wuxiapptec.com Introduction T-cell engagers (TCEs) are …Read More >

Research on cancer immunotherapy has firmly established immune cells as key players in effective cancer treatment. Peptide vaccines directly targeting immune cells have demonstrated immense potential due to their specificity and applicability, but developing peptide vaccines to generate tumor-reactive T cells remains challenging. WuXi AppTec contributed to a review article discussing various elements of effective …Read More >

Introduction: OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we present an evaluation of the efficacy of different JAK subtype inhibitors in a Type II collagen-induced arthritis model, along with corresponding …Read More >

Unlike conventional protein-targeted therapies, nucleic acid therapeutics have the potential for long-lasting effects and greater target specificity. WuXi AppTec provides a comprehensive platform to support the discovery of mRNA drugs.  Our services include mRNA design and production, assessment of mRNA delivery systems, in vitro evaluation, and determination of in vivo efficacy and biodistribution. At AACR …Read More >

Passive Heymann nephritis, induced by intravenous injection of anti-Fx1A in susceptible rat strains, is a complement-dependent model of glomerular disease that resembles membranous nephropathy in humans.  At IMMUNOLOGY2024, WuXi AppTec presented a poster demonstrating that rapamycin exerts a protective effect against anti-Fx1A-induced passive Heymann nephritis by reducing proteinuria.  The authors show that this antiproteinuric effect …Read More >

NK cells are effector innate lymphoid cells (ILCs) that do not require antigen-specific priming. NK cells are not only killer cells that help to suppress tumors, but also are involved in the generation and maintenance of adaptive immune responses.  The process of antibody-dependent cell-mediated cytotoxicity (ADCC) makes use of innate immune cells which provide antitumor …Read More >

Join WuXi AppTec at IMMUNOLOGY2024™. For this year’s annual meeting of the American Association of Immunologists (AAI), WuXi Biology has been selected to present five noteworthy posters, showcasing our panel of preclinical models representing urticaria, nephritis, rheumatoid arthritis, gout, and atopic dermatitis. Stop by Booth 777 to get your questions answered by one of our …Read More >

OncoWuXi Express| Immunology 2024™ Poster Sneak Peek Introduction： OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share with you the highlights of posters we will present at …Read More >

WuXi AppTec provides integrated and cost-effective services for: Polyclonal and monoclonal antibodies Anti-drug antibodies (ADA), host cell protein (HCP) antibodies, surrogate antibodies, diagnostic antibodies, therapeutic antibodies Antibody drug conjugate services, including site-specific conjugation Related antibody services, including peptide design and recombinant protein production